- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06808477
Een studie van BBT001 bij gezonde vrijwilligers (HV's) en bij volwassen patiënten met atopische dermatitis (AD)
Een gerandomiseerde, blinde, placebo-gecontroleerde, dosisonderzoek met één en meervoudig verzettend dosis om de veiligheid, verdraagbaarheid, farmacokinetiek, immunogeniteit, farmacodynamica en klinische activiteit van BBT001 in HVS en AD-patiënten te evalueren in HV's en AD-patiënten
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This study a is a randomized, double-blinded, placebo-controlled single (SAD) and multiple-ascending dose (MAD) study to evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and exploratory clinical activity of BBT001 in healthy volunteers (HVs) and in adult patients with atopic dermatitis. BBT001 is a drug candidate being developed for the treatment of atopic dermatitis.
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Lisa Li
- Telefoonnummer: +1 617-848-6188
- E-mail: Lisa.Li@bambusatx.com
Studie Locaties
-
-
Western Australia
-
Fremantle, Western Australia, Australië, 6160
- Werving
- Fremantle Dermatology
-
Perth, Western Australia, Australië, 6009
- Voltooid
- Linear Clinical Research
-
-
-
-
-
Christchurch, Nieuw-Zeeland
- Werving
- Optimal Clinical Trials Ltd - Christchurch
-
Upper Hutt, Nieuw-Zeeland, 5018
- Werving
- Pacific Clinical Research Network (PCRN) Wellington
-
Contact:
- Tim Humphrey
-
-
Auckland
-
Grafton, Auckland, Nieuw-Zeeland, 1010
- Werving
- Optimal Clinical Trials Central Auckland
-
Contact:
- Arna Letica
-
Otahuhu, Auckland, Nieuw-Zeeland, 2025
- Ingetrokken
- Aotearoa Clinical Trials
-
Takapuna, Auckland, Nieuw-Zeeland, 0622
- Werving
- Pacific Clinical Research Network (PCRN) - Auckland
-
Contact:
- Paul Hamilton
-
-
-
-
-
Lodz, Polen, 91-347
- Werving
- Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
-
Rzeszów, Polen, 35-055
- Werving
- Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
-
Warsaw, Polen, 02-507
- Werving
- Państwowy Instytut Medyczny MSWiA
-
Wroclaw, Polen, 50-566
- Werving
- Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
-
-
-
-
California
-
Irvine, California, Verenigde Staten, 92614
- Werving
- First OC Dermatology
-
-
New York
-
New York, New York, Verenigde Staten, 10128
- Werving
- OptiSkin Medical
-
The Bronx, New York, Verenigde Staten, 10455
- Werving
- Equity Medical, LLC
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria
- Negative pregnancy tests for women of childbearing potential.
- Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
- Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
- Adequate contraception use (for men and women of childbearing potential).
Key Inclusion Criteria (Parts A, B, and D)
- Age of 18-65 years.
- Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
- No clinically significant abnormalities or history of relevant diseases.
Key Inclusion Criteria (Parts C and E only)
- Age of 18-72 years.
- Body mass index ≥16 kg/m², weight capped at 125 kg.
- Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
- Moderate to severe atopic dermatitis
- Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
- Atopic lesions cover ≥10% of body surface area (BSA)
- Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.
Key Exclusion Criteria
- Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
- History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
- Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
- Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
- Abnormal Electrocardiogram (ECG) findings
- History of drug/alcohol abuse in the past 2 years.
- Donated >500mL blood within 2 months of screening.
- History of severe allergic reactions or hypersensitivity.
Key Exclusion Criteria (Parts A, B, and D only)
1. History of atopic dermatitis
Key Exclusion Criteria (Parts C and E only)
- Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
- Receipt of immunoglobulin or blood products within 30 days.
- Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
- Chronic pruritus from conditions other than atopic dermatitis.
- Acute/treated infections or chronic skin infections.
- Current use of sedating antihistamines or corticosteroids.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part A Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers |
BBT001 will be administered |
|
Experimenteel: Part B Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in healthy volunteers. |
BBT001 will be administered |
|
Experimenteel: Part C Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in patients with atopic dermatitis. |
BBT001 will be administered |
|
Placebo-vergelijker: Part A Single Ascending Dose Placebo
A single dose of Placebo will be administered in healthy volunteers |
Placebo will be administered |
|
Placebo-vergelijker: Part B Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in healthy volunteers. |
Placebo will be administered |
|
Placebo-vergelijker: Part C Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in patients with atopic dermatitis. |
Placebo will be administered |
|
Actieve vergelijker: Part D Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers |
BBT001 will be administered |
|
Placebo-vergelijker: Part D Single Ascending Dose Placebo
A single dose of placebo will be administered in healthy volunteers |
Placebo will be administered |
|
Actieve vergelijker: Part E Multiple Ascending Dose BBT001 - Dose Level 1
Multiple doses of BBT001 will be administered in patients with atopic dermatitis. |
BBT001 will be administered |
|
Placebo-vergelijker: Part E Multiple Ascending Dose Placebo
Multiple doses of placebo will be administered in patients with atopic dermatitis. |
Placebo will be administered |
|
Actieve vergelijker: Part E Multiple Ascending Dose BBT001 - Dose Level 2
Multiple doses of BBT001 will be administered in patients with atopic dermatitis |
BBT001 will be administered |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants with adverse events following single and multiple administration of BBT001
Tijdsspanne: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Incidence, relatedness, and severity of adverse events graded per NCI CTCAE v5.0. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in serum blood parameters
Tijdsspanne: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Laboratory assessments include hematology, blood chemistry and coagulation test |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in vital sign measurements following treatment administration.
Tijdsspanne: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Blood pressure and heart rate will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in physical examination following treatment administration.
Tijdsspanne: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Physical examination will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in 12-lead ECG readings
Tijdsspanne: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
12-lead ECG will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pharmacokinetics parameters - maximum observed Concentration (Cmax)
Tijdsspanne: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Maximum observed concentration of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Time for maximum observed Concentration (Tmax)
Tijdsspanne: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Serum PK Tmax will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Area under the curve (AUC)
Tijdsspanne: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Area under the curve of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Volume of distribution (Vz)
Tijdsspanne: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Volume of distribution of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Total clearance (CL)
Tijdsspanne: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Total clearance of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Elimination Half-life (t1/2).
Tijdsspanne: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Elimination half-life of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
The immunogenicity of BBT001 is measured as the number and percentage of subjects who develop Anti-Drug Antibodies (ADA).
Tijdsspanne: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Serum Anti-Drug Antibodies will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Lisa Li, Bambusa Therapeutics, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- BBT001-001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .